Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

A new drug could change everything for children like seven-year-old Liliana, who has Prader-Willi syndrome, a rare genetic ...

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

We recently published a list of 10 Stocks Outperform Broader Market Last Week. In this article, we are going to take a look at where Soleno Therapeutics Inc. (NASDAQ:SLNO) stands against other stocks ...

Soleno Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced that the US Food and Drug Administration (FDA) has approved Vykat XR ...

for its diazoxide cholin—to be called Vykat XR—which aims to treat extreme hunger in patients with Prader-Willi syndrome. The syndrome is a rare genetic disorder caused by abnormalities in ...

1 VYKAT ™ XR is the first and only FDA-approved treatment for hyperphagia in individuals with PWS. PWS is a genetic disorder estimated to occur in approximately one in every 15,000 live births. This ...